Clinical Trial Update: Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of capecitabine for persistent or recurrent cervical cancer has completed (status: COMPLETED).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Cervical Adenosquamous Carcinoma
• Cervical Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Status: COMPLETED